Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (16748)	3/7/1998 8:48:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

tuck, I suspect that the estrogen serum is an (estrogen) SERM, but I doubt that it's the mystery compound from LLY. SERM stand for Selective Estrogen Receptor Modulators and the acronym relates to molecules that produce different effects in different tissues via estrogen receptors. LLY has the only new SERM on the market (Evista, aka Raloxifene) although ZEN's Tamoxifen could also be called a SERM. PFE has two SERMs in clinical trials (Droloxifene and CP-366,156) while AHP is slated to file an IND for another SERM, TSE424 (Tissue Specific Estrogen). LLY is banking on Evista being a blockbuster, so they have a research deal with LGND to see if rexinoids (like Targretin, LGD1268, or LGD1324) can synergize of enhance the SERM. The compound that LGND could get from LLY would target a much smaller market. The strong speculation is that the drug in question is SRGN's DAB IL-2 fusion protein for treating CTCL.